Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 57Stomach Neoplasms 45Carcinoma, Non-Small-Cell Lung 36Colorectal Neoplasms 24Esophageal Squamous Cell Carcinoma 19Rectal Neoplasms 11Lung Neoplasms 11Esophageal Neoplasms 11Nasopharyngeal Carcinoma 10Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Pancreatic Neoplasms 7Neoplasm Metastasis 7Cholangiocarcinoma 6Uterine Cervical Neoplasms 5Small Cell Lung Carcinoma 5Triple Negative Breast Neoplasms 4Recurrence 4Liver Neoplasms 4Endometrial Neoplasms 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Solid Tumor 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Extranodal NK-T-Cell 3Colorectal Cancer Metastatic 3Carcinoma 3Breast Neoplasms 3Advanced Solid Tumors 3Advanced Solid Tumor 3

Interventions

Gemcitabine 60Cisplatin 38Oxaliplatin 30Capecitabine 28Fluorouracil 21Leucovorin 19pembrolizumab 11Irinotecan 11durvalumab 9130-nm albumin-bound paclitaxel 9Erlotinib Hydrochloride 8Trastuzumab 7Bevacizumab 7Platinum 6Magnetic Resonance Spectroscopy 6Albumin-Bound Paclitaxel 61,2-diaminocyclohexaneplatinum II citrate 6Taxes 5Specimen Handling 5Sorafenib 5Radiotherapy 5Carboplatin 5Docetaxel 4Biopsy 4trifluridine tipiracil drug combination 3dehydroftorafur 3atezolizumab 3Paclitaxel 3Lapatinib 3Interleukin-12 Subunit p35 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Gallbladder Neoplasms × sintilimab × Clear all
NCT05757336 2023-03-07

Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer

Fudan University

Phase 2 Recruiting
50 enrolled
Gastrointestinal

Gallbladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡